Want to join the conversation?
Biopharmaceutical company $CELG and the Lymphoma Study Association (LYSA) said the Lymphoma Academic Research Organisation (LYSARC) has reported initial data from a Phase III randomized double-blind study, REMARC. Study achieved primary endpoint of a significant improvement in progression-free survival for patients receiving REVLIMID.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.